The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.

GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...

CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Explore SGMT's breakthrough MASH therapy, Denifanstat, with FDA designation & Phase 3 progress. Click here to read my most ...

Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected ...

Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...

The data analyses showed clinically meaningful and dose-dependent anti-dyskinetic effects of mesdopetam, although the primary efficacy endpoint, good ON-time, was not met in this Phase IIb study.

Investing.com -- Shares of Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX) tumbled 55% after the company announced topline results from its PROGRESS Phase 2b study, which evaluated pilavapadin in ...

GOTHENBURG, SWEDEN / ACCESS Newswire / February 27, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 27, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a compa ...

The AHFIRM trial did not demonstrate a beneficial effect of larsucosterol on 90-day mortality or the need for liver transplant among patients with severe alcohol-associated hepatitis, or AH, according ...